0001140361-23-018047.txt : 20230412 0001140361-23-018047.hdr.sgml : 20230412 20230412190022 ACCESSION NUMBER: 0001140361-23-018047 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230404 FILED AS OF DATE: 20230412 DATE AS OF CHANGE: 20230412 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: White Mark Andrew CENTRAL INDEX KEY: 0001973240 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36829 FILM NUMBER: 23816740 MAIL ADDRESS: STREET 1: C/O ROCKET PHARMACEUTICALS, INC. STREET 2: 9 CEDARBROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ROCKET PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001281895 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 350 FIFTH AVENUE STREET 2: SUITE 7530 CITY: NEW YORK STATE: NY ZIP: 10118 BUSINESS PHONE: 646-440-9100 MAIL ADDRESS: STREET 1: 350 FIFTH AVENUE STREET 2: SUITE 7530 CITY: NEW YORK STATE: NY ZIP: 10118 FORMER COMPANY: FORMER CONFORMED NAME: INOTEK PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20040226 4 1 form4.xml X0407 4 2023-04-04 0001281895 ROCKET PHARMACEUTICALS, INC. RCKT 0001973240 White Mark Andrew C/O ROCKET PHARMACEUTICALS, INC. 9 CEDARBROOK DRIVE CRANBURY NJ 08512 true Chief Medical Officer false Common Stock, par value $0.01 2023-04-04 4 A 0 76662 0 A 76662 D Stock Option (Right to Buy) 17.41 2023-04-04 4 A 0 57739 0 A 2033-04-04 Common Stock 57739 57739 D Holdings are Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on April 4, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. This option represents a right to purchase a total of 57,739 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on April 4, 2024, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. /s/ Martin Wilson, as attorney-in-fact for Mark Andrew White 2023-04-12